Fredun Pharmaceuticals Ltd. (FREDUN) — Tipsheet

Fredun targets 25-30% growth in FY27, eyes ₹100 cr mobility run rate

Tipsheet Editorial — Fri, 12 Jun 2026 19:30:29 GMT

Transcript details plans for hormonal therapies, anti-aging, and pet care platform Wagr; management targets PAT margins of 10-12% in medium term.

What’s new

Plans to enter hormonal therapies and anti-aging with first/second-in-India products.
Pet care division to launch Wagr platform in July; earned ₹42-43 cr in FY26.
Mobility revenue of ₹30 cr set to reach ₹100 cr run rate within 2.5 years.

Why it matters

Fredun is pivoting from generic pharma to higher-margin consumer and mobility verticals. The 10-12% PAT margin target implies a significant improvement from current profitability levels, supported by the mix shift. If achieved, the stock's 38.9x P/E could find justification in earnings acceleration.

What we’re watching

Wagr platform traction and revenue contribution post-July launch.
Regulatory clearances and market entry for hormonal/anti-aging products.
Quarterly mobility revenue trajectory toward ₹100 cr run rate.

The full read

Fredun's earnings call transcript fleshes out the pivot outlined in the June 10 concall. The new details are concrete: entry into hormonal therapies and anti-aging with first- or second-in-India products, a July launch for the pet care platform Wagr, and a mobility target of ₹100 crore run rate within 2.5 years from the current ₹30 crore. The growth guidance of 25-30% for FY27 matches the trailing 27% revenue growth, but the real story is whether margins improve as new businesses scale. Management is targeting a PAT margin of 10-12% in the medium term, betting that higher-margin consumer and mobility businesses will lift profitability from current levels. The 10-12% target implies a significant improvement over the trailing ROE of 11.7%. If execution holds, a 38.9x P/E may prove justified. The risks are regulatory timelines and consumer adoption, but the direction is clear.

Primary source: BSE · NSE

Fredun pivots to pet care and physiotherapy, guides 25-30% revenue growth for FY27

Tipsheet Editorial — Wed, 10 Jun 2026 12:07:59 GMT

New-age consumer businesses grew at 40-50% CAGR and already deliver 55% gross margins, a stark contrast to the 20% from its core pharma contract manufacturing.

What’s new

Fredun is pivoting from contract manufacturing to a consumer-focused company, launching Wagga pet platform and Mobilitix physiotherapy brand.
New-age businesses (pet care, mobility, nutraceuticals, cosmetics) grew at 40-50% CAGR with 45-55% gross margins.
Management guided for 25-30% topline growth in FY27 and targets 10-12% PAT margins within a few years.

Why it matters

Fredun is making a hard pivot from a low-margin, cyclical contract manufacturing business to higher-margin, direct-to-consumer brands. The scale of the margin differential (20% vs. 55%) justifies the strategic shift, but the company is essentially building a new business alongside its old one. Execution risk is high.

What we’re watching

Adoption metrics for the Wagga and Mobilitix launches in H1 FY27.
Whether the 25-30% topline growth guide is met without margin dilution.
The path to ₹100 crore run-rate for the mobility business.

The full read

Fredun Pharmaceuticals is remaking itself. The 19-year-old contract manufacturer, which has never had a year of revenue decline, is now building consumer brands in pet care and physiotherapy. The logic is clear: its legacy pharma business generates 20% gross margins. The new ventures are already hitting 45-55% and growing at a 40-50% CAGR. Management guided for 25-30% topline growth in FY27 and is targeting 10-12% PAT margins in time. The first test comes in weeks, with the soft launch of the Wagga pet platform and the Mobilitix physiotherapy brand. The mobility business did ₹30 crore last year and aims for a ₹100 crore run rate in 2.5 years. The pivot is ambitious. The margin math justifies it. The question is execution.

Primary source: BSE · NSE

Fredun Pharmaceuticals posts 60% profit jump and declares 2:1 bonus

Tipsheet Editorial — Mon, 25 May 2026 22:07:05 GMT

Annual revenue climbed 40% to ₹633.3 crore as the board approved a five-fold expansion of authorised capital to support the bonus issue.

What’s new

FY26 net profit hit ₹33.2 crore, a 60% increase over the prior year.
Revenue rose 40% to ₹633.3 crore for the year ended March 2026.
Board approved a 2:1 bonus issue and a final dividend of 70 paise per share.

Why it matters

The combination of strong earnings growth and a significant bonus issue signals management's confidence in the company's cash position. While the auditor flagged a procedural delay in transferring unclaimed dividends, the core financial performance remains the primary takeaway for shareholders.

What we’re watching

Shareholder approval for the increase in authorised share capital to ₹50 crore.
The record date for the bonus share distribution.
Resolution of the auditor's note regarding the Investor Education and Protection Fund.

The full read

Fredun Pharmaceuticals delivered a strong fiscal year, with revenue climbing 40% to ₹633.3 crore and net profit surging 60% to ₹33.2 crore. To mark the performance, the board declared a 2:1 bonus issue and a final dividend of 70 paise per share. The company is also moving to expand its authorised share capital five-fold, from ₹10 crore to ₹50 crore, to facilitate the bonus and provide headroom for future growth. While the auditor issued an unmodified opinion, they flagged a technical lapse regarding the transfer of unclaimed dividends to the Investor Education and Protection Fund. For a micro-cap, the scale of these corporate actions is unusual. The next test for the company is securing shareholder approval for the capital expansion and executing the bonus distribution without further regulatory friction.

Primary source: BSE · NSE

Fredun Pharmaceuticals lifts profit 60% and declares 2:1 bonus

Tipsheet Editorial — Mon, 25 May 2026 21:54:48 GMT

Annual profit hit ₹33.2 crore on a 40% revenue jump to ₹633 crore. The board also hiked authorised capital five-fold to ₹50 crore.

What’s new

Annual revenue rose 40% to ₹633 crore for FY26.
Net profit climbed 60% to ₹33.2 crore.
Authorised share capital will increase from ₹10 crore to ₹50 crore.

Why it matters

The combination of strong earnings growth and a significant bonus issue signals management confidence in the company's cash flow. Expanding the authorised capital suggests the firm is preparing for further growth or potential equity-based financing.

What we’re watching

The record date for the 2:1 bonus issue.
Utilization of the expanded authorised capital.
Production output from the upgraded Palghar facility.

The full read

Fredun Pharmaceuticals ended FY26 with a 40% rise in revenue to ₹633 crore and a 60% jump in net profit to ₹33.2 crore. The company attributes these gains to cost management and operating efficiency. To mark the performance, the board declared a 2:1 bonus issue and a final dividend of 70 paise per share. The company is also preparing for future expansion by increasing its authorised share capital from ₹10 crore to ₹50 crore. These moves follow a year of capacity additions and warrant conversions. With a recent credit rating upgrade and ongoing investments in its Palghar facility, the company is signaling a shift toward a larger scale of operations. The bonus issue and capital hike are the clearest indicators that management expects this growth trajectory to continue.

Primary source: BSE · NSE

Fredun Pharma's profit jumps 60%, declares 2:1 bonus

Tipsheet Editorial — Mon, 25 May 2026 17:53:11 GMT

FY26 revenue rose 40% to ₹639 crore, but profit grew faster at 60%. The board proposed two new shares for every one held and a final dividend.

What’s new

Fredun's FY26 total income rose 40% to ₹639 crore, with EBITDA up 72% to ₹94.8 crore.
Net profit climbed 60% to ₹33.2 crore on cost discipline and a balanced product mix.
Board proposed a 2:1 bonus issue and a final dividend of ₹0.70 per share.

Why it matters

Profit growing faster than revenue is a sign the business is scaling efficiently. Pairing the strong results with a bonus issue and dividend signals management intends to return cash to shareholders now.

What we’re watching

Whether the Palghar capacity expansion translates into further profit growth in FY27.
The impact of the IVR BBB+ credit rating upgrade on borrowing costs.
Sustainability of demand across its generics, nutraceuticals, and pet pet care segments.

The full read

Fredun Pharmaceuticals delivered a strong year. Revenue rose 40% to ₹639 crore. Profit grew faster: EBITDA jumped 72% to ₹94.8 crore and net profit climbed 60% to ₹33.2 crore. That points to costs being well contained as the business scaled. The company is expanding its Palghar facility and pointed to a credit upgrade to IVR BBB+ as evidence of improved financial standing. The board is sharing the gains, proposing a 2:1 bonus and a final dividend of ₹0.70 per share. The financial trajectory is clear. The next test is whether the new capacity can sustain the pace in FY27.

Primary source: BSE · NSE

Fredun's profit jumps 60%, board declares 2:1 bonus

Tipsheet Editorial — Mon, 25 May 2026 14:59:14 GMT

FY26 revenue hit Rs. 633.3 crore, with net profit climbing to Rs. 33.2 crore. The board also proposed a final dividend of 70 paise per share.

What’s new

FY26 standalone revenue rose 40% to Rs. 633.3 crore; net profit surged 60% to Rs. 33.2 crore.
The board recommended a 2:1 bonus issue and a final dividend of 70 paise per share.
Authorised share capital will be raised from Rs. 10 crore to Rs. 50 crore, subject to shareholder approval.

Why it matters

The strong earnings beat confirms the company's growth in its pharma segment. The 2:1 bonus signals management confidence, while the five-fold increase in authorised capital creates room for future equity issuances. The results were ahead of market expectations for a micro-cap.

What we’re watching

How the market prices the bonus issue ahead of the record date.
The company's next capital-raising plans now that authorised capital is being expanded.
Whether the 40% revenue growth rate can be sustained into FY27.

The full read

Fredun Pharmaceuticals closed FY26 with 40% revenue growth to Rs. 633.3 crore and a 60% jump in net profit to Rs. 33.2 crore. The performance, led by its pharma and healthcare segment, came alongside a 2:1 bonus and a final dividend of 70 paise per share. The bonus aims to improve liquidity, a common move for micro-caps after strong growth. More strategically, Fredun is raising its authorised share capital five-fold, from Rs. 10 crore to Rs. 50 crore, clearing the path for future equity raises if needed. The results were strong. The corporate actions are now in motion. The open question is whether the operational growth can be sustained to fill that new capital headroom.

Primary source: BSE · NSE